Low Tidal Volume Ventilation for Cardiac Surgery
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial tests different methods of assisting breathing during heart surgery to determine which is safer and reduces lung problems post-operation. It compares three methods: continuous low tidal volume ventilation with normal oxygen levels (FiO2 of 0.21), continuous low tidal volume ventilation with high oxygen levels (FiO2 of 1.0), and apnea during cardiopulmonary bypass without extra oxygen. Patients undergoing planned heart surgeries that require a heart-lung machine may be suitable candidates. The trial aims to improve post-surgery recovery by identifying the optimal breathing method. As an unphased trial, it allows patients to contribute to significant research that could enhance surgical recovery for future patients.
Do I need to stop my current medications for this trial?
The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.
What prior data suggests that these ventilation strategies are safe for cardiac surgery patients?
Research shows that low tidal volume ventilation is generally safe for patients. This method is already a standard treatment for people with acute respiratory distress syndrome (ARDS). Studies have found that using low tidal volume during surgeries can protect the lungs and may lower the risk of lung problems afterward.
This trial examines two versions of low tidal volume ventilation: one with normal oxygen levels (FiO2 0.21) and one with pure oxygen (FiO2 1.0). FiO2 refers to the amount of oxygen in the air given to patients. Previous studies support the safety of using low tidal volume with either oxygen level, suggesting it does not increase the risk of complications. In fact, it might help keep the lungs healthier during surgery.12345Why are researchers excited about this trial?
Researchers are excited about this trial because it explores unique ventilation approaches during cardiac surgery that could significantly impact patient outcomes. Unlike standard practices that often use higher tidal volumes or fixed oxygen levels, this trial examines continuous low tidal volume ventilation with varying oxygen concentrations (FiO2 of 0.21 and 1.0). The goal is to understand how these methods affect postoperative pulmonary complications (PPCs) and mortality rates. By investigating the effects of hyperoxia avoidance and apnea, the trial aims to refine ventilation strategies, potentially leading to safer procedures and better recovery for patients undergoing cardiac surgery.
What evidence suggests that this trial's ventilation strategies could be effective for reducing mortality and postoperative pulmonary complications?
This trial will compare different ventilation strategies during cardiac surgery. Research has shown that low tidal volume ventilation can reduce complications and improve outcomes for heart surgery patients. This method uses smaller breaths to protect the lungs, lowering the risk of lung injuries. In this trial, one arm will use continuous low tidal volume ventilation with an oxygen level (FiO2) of 0.21. Studies have found this reduces lung damage and improves survival rates. Another arm will use low tidal volume ventilation with an oxygen level (FiO2) of 1.0, which has effectively reduced complications after surgery, especially for those with existing lung issues. Both approaches aim to protect the lungs during surgery, leading to better recovery and fewer problems afterward.36789
Who Is on the Research Team?
Marta Kelava, MD
Principal Investigator
The Cleveland Clinic
Are You a Good Fit for This Trial?
Adults over 18 years old needing elective cardiac surgery with cardiopulmonary bypass can join. It's not for those requiring one-lung ventilation, emergency surgeries, lung or heart transplants, or mechanical circulatory support device implantation.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants undergo cardiopulmonary bypass with different ventilation strategies to evaluate effects on mortality and pulmonary complications
Follow-up
Participants are monitored for postoperative complications and mortality within 30 days of surgery
Sub-study
Sub-study investigates 8-iso-prostaglandin F2a and sRAGE levels during CPB
What Are the Treatments Tested in This Trial?
Interventions
- Apnea During CPB
- Continuous low-tidal volume ventilation with using FiO2 of 0.21
- Continuous low tidal volume ventilation with using FiO2 of 1.0
Continuous low-tidal volume ventilation with using FiO2 of 0.21 is already approved in United States, European Union, Canada for the following indications:
- Cardiac surgery
- Prevention of postoperative pulmonary complications
- Cardiac surgery
- Prevention of postoperative pulmonary complications
- Acute respiratory distress syndrome
- Cardiac surgery
- Prevention of postoperative pulmonary complications
Find a Clinic Near You
Who Is Running the Clinical Trial?
The Cleveland Clinic
Lead Sponsor
Society of Cardiovascular Anesthesiologists
Collaborator
University of Pittsburgh Medical Center
Collaborator
Ohio State University
Collaborator